Free Trial

Takeda Pharmaceutical (TAK) Earnings Date, Estimates & Call Transcripts

Takeda Pharmaceutical logo
$14.10 +0.11 (+0.75%)
Closing price 05/16/2025 03:59 PM Eastern
Extended Trading
$14.10 0.00 (0.00%)
As of 05/16/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Earnings Summary

Takeda Pharmaceutical released Q4 2025 earnings on May 8, 2025, reporting an EPS of $0.16, which missed analysts' consensus estimates of $0.24 by $0.08. Quarterly revenue was reported to be $7.34 billion, below analysts' expectations of $8.02 billion. With a trailing EPS of $0.22 and a P/E Ratio of 35.26, Takeda Pharmaceutical's earnings are expected to grow 0.61% next year, from $1.64 to $1.65 per share.

Upcoming Q1
Earnings Date
Jul. 30Before Market OpensEstimated
Consensus EPS
(May. 8)
$0.24
Actual EPS
(May. 8)
$0.16 Missed By -$0.08
Actual Revenue
(May. 8)
$7.34B

Q4 2025 Earnings Resources

TAK Upcoming Earnings

Takeda Pharmaceutical's next earnings date is estimated for Wednesday, July 30, 2025, based on past reporting schedules.

Get Takeda Pharmaceutical Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Takeda Pharmaceutical and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

TAK Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TAK Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Takeda Pharmaceutical Analyst EPS Estimates

Current Year EPS Consensus Estimate
$1.64 EPS
Next Year EPS Consensus Estimate
$1.65 EPS

Takeda Pharmaceutical Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
7/30/2025
(Estimated)
--------
5/8/2025Q4 2025$0.24$0.16 -$0.08-$0.21$8.02B$7.34B
1/30/2025Q3 2025$0.34$0.42+$0.08$0.05--
7/31/2024Q1 2025$0.37$0.56+$0.19$0.93-$7.75B
2/1/2024Q3 2024-$0.51+$0.51$0.79-$7.52B
10/26/2023Q2 2024-$0.50+$0.50$0.86-$6.94B
7/27/2023Q1 2024-$0.55+$0.55$0.89-$7.71B

Takeda Pharmaceutical Earnings - Frequently Asked Questions

Takeda Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 30th, 2025 based off last year's report dates. Learn more on TAK's earnings history.

Takeda Pharmaceutical updated its FY 2025 earnings guidance on Thursday, May, 8th. The company provided earnings per share (EPS) guidance of 3.180-3.180 for the period. The company issued revenue guidance of $29.7 billion-$29.7 billion.

In the previous quarter, Takeda Pharmaceutical (NYSE:TAK) missed the analysts' consensus estimate of $0.24 by $0.08 with a reported earnings per share (EPS) of $0.16. Learn more on analysts' earnings estimate vs. TAK's actual earnings.

The conference call for Takeda Pharmaceutical's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Takeda Pharmaceutical's latest earnings report can be read online.
Read Transcript

Takeda Pharmaceutical (NYSE:TAK) has a recorded annual revenue of $4.58 trillion.

Takeda Pharmaceutical (NYSE:TAK) has a recorded net income of $994.06 million. TAK has generated $0.22 earnings per share over the last four quarters.

Takeda Pharmaceutical (NYSE:TAK) has a trailing price-to-earnings ratio of 35.26 and a forward price-to-earnings ratio of 8.60. The price/earnings-to-growth ratio is 0.24.

Takeda Pharmaceutical's earnings are expected to grow from $1.64 per share to $1.65 per share in the next year, which is a 0.61% increase.

More Earnings Resources from MarketBeat



This page (NYSE:TAK) was last updated on 5/17/2025 by MarketBeat.com Staff
From Our Partners
OSZAR »